5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line

Journal of Applied Toxicology

Volumn 29, Issue 4, 2009, Pages 308-316

  Matuo, Renata ^a   Sousa, Fabrício Garmus ^a   Escargueil, Alexandre E ^b,c,d,e   Grivicich, Ivana ^f   Garcia Santos, Daniel ^a   Chies, José Artur Bogo ^a   Saffi, Jenifer ^a,g   Larsen, Annette K ^b,c,d   Pêgas Henriquesa, João Antonio ^a,e,g  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITY OF CAXIAS DO SUL   (Brazil)

^f UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^g Universidade Luterana Brasileira   (Brazil)

Author keywords

5 fluorouracil; Apoptosis; Cell cycle arrest; Cytotoxicity; FdUMP; Genotoxicity

Indexed keywords

DRUG METABOLITE; FLUORODEOXYURIDINE MONOPHOSPHATE; FLUOROURACIL; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; GENOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SINGLE STRANDED DNA BREAK;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DNA, NEOPLASM; FLUORODEOXYURIDYLATE; FLUOROURACIL; HISTONES; HUMANS; MICRONUCLEUS TESTS; MUTAGENS;

EID: 65649089859     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1411     Document Type: Article

References (38)

1. Amarante-Mendes GP, Bossy-Wetzel E, Brunner T, Green DR. 1998. Apoptosis assay. In Cell: A Laboratory Manual, Spector DL, Goldman R, Leinwand L (eds). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 15.1-15.24.
2. Bastiani M, Vidotto MC, Horn F. 2005. An avian pathogenic Escherichia coli isolate induces caspase 3/7 activation in J774 macrophages. FEMS Microbiol. Lett. 253: 133-140. (Pubitemid 41605405)
3. Berger SH, Pittman DL, Wyatt MD. 2008. Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem. Pharmacol. 76: 697-706.
4. Burlinson B, Tice RR, Speit G, Agurell E, Brendler-Schwaab SY, Collins AR, Escobar P, Honma M, Kumaravel TS, Nakajima M, Sasaki YF, Thybaud V, Uno Y, Vasquez M, Hartmann A. 2007. Fourth International Workgroup on Genotoxicity Testing: results of the in vivo comet assay workgroup. Mutat. Res. 627: 31-35. (Pubitemid 46091764)
5. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland R. 1999. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117: 123-131. (Pubitemid 29297628)
6. Collins AR. 2004. The comet assay for DNA damage and repair: principles, applications and limitations. Mol. Biotechnol. 26: 249-261. (Pubitemid 41490465)
7. Curtin NJ, Harris AL, Aherne GW. 1991. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. 51: 2346-2352.
8. Fisher F, Baerenfaller K, Jiricny J. 2007. 5-Fluorouracil is efficiently removed from DNA by the base excision and mismatch repair systems. Gastroenterology 133: 1858-1868. (Pubitemid 350180806)
9. Grem JL. 1997. Mechanisms of action and modulation of fluorouracil. Semin. Radiat. Oncol. 7: 249-259. (Pubitemid 27444407)
10. GrivicichI,RegnerA,RochaAB,GrassLB,AlvesPAG,KayserGB,SchwartsmannG, HenriquesJAP.2005.Irinotecan/5- fluorouracilcombinationinducesalterationsinmitochondrialmembranepotential andcaspasesoncoloncancercelllines.Oncol.Res.15:1-8.(Pubitemid43198595)
11. Harvey AC, Jackson SP, Downs JA. 2005. Saccharomyces cerevisiae Histone H2A Ser122 facilitates DNA repair. Genetics 170: 543-553. (Pubitemid 40980658)
12. Li L, Connor EE, Berger SH, Wyatt MD. 2005. Determination of apoptosis, uracil incorporation, DNA strand breaks, and sister chromatid exchanges under conditions of thymidylate deprivation in a model of BER deficiency. Biochem. Pharmacol. 70: 1458-1468. (Pubitemid 41483456)
13. Liao ZY, Sordet O, Zhang HL, Kohlhagen G, Antony S, Gmeiner WH, Pommier Y. 2005. A novel polypyrimidine antitumor agent FdUMP[10] induces thymidineless death with topoisomerase I - DNA complexes. Cancer Res. 65: 4844-4851. (Pubitemid 40740823)
14. Longley DB, Allen WL, McDermott U, Wilson TR, Latif T, Boyer J, Lynch M, Johnston PG. 2004. The roles of thymidylate synthase and p53 in regulation mediated apoptosis in response to antimetabolites. Clin. Cancer Res. 10: 3562-3571. (Pubitemid 38685467)
15. Lorge E, Thybaud V, Aardema MJ, Oliver J, Wakata A, Lorenzon G, Marzin D. 2006. SFTG international collaborative study on in vitro micronucleus test I. General conditions and overall conclusions of the study. Mutat. Res. 607: 13-36. (Pubitemid 44026678)
16. Luo Y, Walla M, Wyatt MD. 2008. Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase. DNA Repair 7: 162-169.
17. Matsushima T, Hayashi M, Matsuoka A, Ishidate Jr. M, Miura KF, Shimizu H, Suzuki Y, Morimoto K, Ogura H, Mure K, Koshi K, Sofuni T. 1999. Validation study of the in vitro micronucleus test in a Chinese hamster lung cell line (CHL/IU). Mutagenesis 14: 569-580.
18. MaybaumJ,UllmanB,MandelHG,DayJL,SadeeW.1980. RegulationofRNAandDNAdirectactionsof5-fluoropyrimidinesinmouseT-lymphoma(S49) cells.CancerRes.40:4209-4215.(Pubitemid10030452)
19. McGahon AJ, Martin SJ, Bissonnette RP, Mahboudi A, Shi Y, Mogil RJ, Nishioka WK, Green DR. The end of the (cell) line: methods for the study of apoptosis in vitro. In Methods in Cell Biology, Schurartz LM, Osbourne BA (eds), Vol.46. Academic Press: London, 1995; 153-184.
20. Meyers M, Hwang A, Wagner MW, Bruening AJ, Veigl ML, Sedwick WD, Boothman DA. 2003. A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage. Oncogene 22: 7376-7388.
21. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. 2005. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J. Biol. Chem. 280: 5516-5526. (Pubitemid 40280029)
22. Noordhuis P, Holwerda U, van der Wilt CL, van Groening CJ, Smid K, Meijer S, Pinedo HM, Peters GJ. 2004. 5-fluorouracil incorporation into RNA and DNA in relation to thymidilate synthase inhibition of human colorectal cancers. Ann. Oncol. 15: 1025-1032. (Pubitemid 39089778)
23. Oka H, Ikeda K, Yoshimura H, Ohuchida A, Honma M. 2006. Relationship between p53 status and 5-fluorouracil sensitivity in 3 cell lines. Mutat. Res. 606: 52-60. (Pubitemid 44236071)
24. Oliver J, Meunier JR, Awogi T, Elhajouji A, Ouldelhkin MC, Bichet N, Thybaud V, Lorenzon G, Marzin D, Lorge E. 2006. SFTG international collaborative study on in vitro micronucleus test V. Using L5178Y cells. Mutat. Res. 607: 125-152. (Pubitemid 44026682)
25. Pizzorno G, Sun Z, Handschumacher RE. 1995. Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil. Biochem. Pharmacol. 49: 553-557.
26. Rahman Z, Kohli K, Khar RK, Ali M, Charoo NA, Shamsher AAA. 2006. Characterization of 5-fluorouracil microspheres for colonic delivery. AAPS PharmSciTech 7: 1-9. (Pubitemid 43840597)
27. Seiple L, Jaruga P, Dizdaroglu M, Stivers JT. 2006. Linking uracil base excision repair and 5-fluorouracil toxicity in yeast. Nucl. Acids Res. 34: 140-151. (Pubitemid 43167920)
28. Shewach DS, Lawrence TS. 2007. Antimetabolites radiosensitizers. J. Clin. Oncol. 25: 4043-4050.
29. SkehanP,StorengR,ScudieroD,MonksA,McMahonJ,VisticaD,WarrenJT,BokeschH, KenneyS,BoydMR.1990.Newcolorimetriccytotoxicityassayforanticancer-drugscreening. J.Natl.CancerInst.13:1107-1112.(Pubitemid20213250)
30. Skladanowski A, Côme M-J, Sabisz M, Escargueil AE, Larsen AK. 2005. Down-regulation of DNA topoisomerase IIα leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule- interacting agents. Mol. Pharmacol. 68: 625-634. (Pubitemid 41206016)
31. Soares DG, Escargueil AE, Poindessous V, Sarasin A, Gramont A, Bonatto D, Henriques JAP, Larsen AK. 2007. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl Acad. Sci. USA 104: 13062-13067.
32. Tice RR, Agurell E, Anderson D, Burinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sassaki YF. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35: 206-221. (Pubitemid 30196665)
33. Tokunaga E, Oda S, Fukushima M, Maehara Y, Sugimachi K. 2000. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur. J. Cancer 36: 1998-2006.
34. Wang ZB, Liu YQ, Cui YF. 2005. Pathways to caspase activation. Cell Biol. Int. 29: 489-496. (Pubitemid 41138210)
35. Webley SD, Hardcastle A, Ladner RD, Jackman AL, Aherne GW. 2000. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br. J. Cancer 83: 792-799.
36. Webley SD, Hardcastle A, Ladner RD, Jackman AL, Aherne GW. 2001. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase inhibition. Br. J. Cancer 85: 446-452 (Pubitemid 32747716)
37. Welsh SJ, Hobbs S, Aherne GW. 2003. Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition. Eur. J. Cancer 39: 378-387. (Pubitemid 36140057)
38. Werner JM, Steinfelder HJ. 2008. A microscope technique to study kinetics and concentration - response of drug induced caspase 3 activation on a single cell level. J. Pharmacol. Toxicol. Meth. 2: 131-137.